Search results
Showing 1846 to 1860 of 2581 results for methods
Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270
Discontinued Reference number: GID-TA10211
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]
Discontinued Reference number: GID-TA10830
Discontinued Reference number: GID-TA11338
Mental health of adults in contact with the criminal justice system (QS163)
This quality standard covers recognising, assessing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system (this includes police contact, court and prison custody, street triage, liaison and diversion services, and probation services). It describes high-quality care in priority areas for improvement.
View quality statements for QS163Show all sections
This quality standard covers assessing and managing motor neurone disease, including care, support and planning after diagnosis. It describes high-quality care in priority areas for improvement.
View quality statements for QS126Show all sections
Sections for QS126
- Quality statements
- Quality statement 1: Information and support at diagnosis
- Quality statement 2: Respiratory assessment and non-invasive ventilation
- Quality statement 3: Provision of equipment and adaptions based on multidisciplinary team assessment
- Quality statement 4: Continuity of care
- Quality statement 5: Planning for end of life care
- About this quality standard
view that these expensive interventions should only be used when other methods (digital CBT and group-based interventions) have been...
view that these expensive interventions should only be used when other methods (digital CBT and group-based interventions) have been...
Belatacept for the prevention of organ rejection in kidney transplantation [ID87]
Discontinued Reference number: GID-TAG239
In development Reference number: GID-TA11273 Expected publication date: TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
In development Reference number: GID-TA11010 Expected publication date: TBC
Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]
Discontinued Reference number: GID-TA10686
Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]
Discontinued Reference number: GID-TA11151
Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]
Discontinued Reference number: GID-TAG408
In development Reference number: GID-TA10467 Expected publication date: TBC
In development Reference number: GID-TAG388 Expected publication date: TBC